About Lakeshore Biomaterials

Arthur J. Tipton, PhD, Vice President, SurModics and President, Brookwood Pharmaceuticals, joined Southern Research in 2004 to lead the formation of a new company based on Southern’s pharmaceutical formulations business. Brookwood Pharmaceuticals was launched in January 2005 with Dr. Tipton as President and CEO. He also directed the acquisition of Alkermes’ external polymer business which was completed in November 2004. Lakeshore Biomaterials, is a division of Brookwood Pharmaceuticals.

Immediately prior to joining Southern, Dr. Tipton served as Executive Vice President at Durect Corporation, a California-based, publicly traded drug delivery company. Dr. Tipton held a variety of positions in Southern BioSystems, including Vice President and Chief Scientific Officer where he led all efforts on biodegradable technology from 1993-2001. At Southern BioSystems he invented the SABER Delivery System and led its development into multiple clinical campaigns. He was a part of the negotiating team for acquisition of Southern BioSystems by Durect. Prior to joining Southern BioSystems, Dr. Tipton was with Atrix Laboratories (now part of QLT) from 1988-1993.

During his career, his development efforts have led to the launch of four commercial products. He holds 22 US patents with numerous foreign equivalents, and has more than 60 publications, presentations and invited lectures to his credit. Dr. Tipton earned his PhD in Polymer Science and Engineering from the University of Massachusetts, Amherst. He has previously served on the Boards of the Society for Biomaterials and Southern BioSystems, and currently serves on the Boards of Brookwood Pharmaceuticals, the Biotechnology Association of Alabama, and the Controlled Release Society.

Paul Spencer, Vice President, Brookwood Pharmaceuticals and General Manager Lakeshore Biomaterials, brings more than 20 years of leadership experience including over 14 years in the drug delivery and medical device industries. Prior to joining Brookwood, he worked in the Business Development Group at Alkermes. His primary responsibility was the Alkermes’ Medisorb® bioabsorbable polymer division, which included worldwide sales and marketing, business strategy, product development, and customer service. Mr. Spencer’s experience includes being a top sales consultant and distributor at Biomet’s Subsidiary, W’Lorenz Surgical, where he was involved in the launch and commercialization of the world’s first Craniomaxillofacial absorbable plating system. He also served over six years as a U.S. Army Aviation Officer in the U.S. and abroad. Mr. Spencer holds a BS in Quantitative Business Analysis from Indiana University.

John Middleton, PhD, Vice President, Brookwood Pharmaceuticals - Operations, brings a wealth of experience in leading technical and operational teams in polymer manufacture and in the development of drug delivery products.  He has been synthesizing biodegradable polymers since the early 1980s.  As the Vice President and Technical Director of Birmingham Polymers (BPI), he directed the day-to-day operations of BPI from 1996-2001.  During that time he was involved in the synthesis of over 600 batches of polymer and the commercialization of five products.   As a Director of Product Development at Durect from 2001-2003, Dr. Middleton lead technical teams on programs at the both bench and clinical level.   Previous to his roles in Birmingham Polymers and Durect, Dr. Middleton worked in the industrial fiber business for Monsanto (now Solutia).  Dr. Middleton has published 18 articles in scientific and trade journals and holds two patents.   He received his doctorate in Polymer Science from the University of Southern Mississippi.

F. Reese Frazer, Senior Director, Brookwood Pharmaceuticals - Licensing and Strategic Affairs, has more than 14 years of experience managing intellectual properties and contracts.  He previously assisted with the management of the intellectual property portfolio of Southern Research Institute, and prior to that, spent seven years in the drug delivery industry at Southern BioSystems, Inc. (currently Durect Corporation.) There Mr. Frazer was responsible for directing the licensing and patenting of intellectual property and oversight of the company's contract portfolio. He has additional experience in a variety of areas of corporate management.  As a microbiologist, he conducted R&D projects in a range of scientific disciplines leading to 15 publications.  Mr. Frazer earned his MBA from the University of Alabama at Birmingham, and his BS in Microbiology from Auburn University, Alabama.

Linda L. Moran, CPA, Senior Director, Brookwood Pharmaceuticals - Finance, has more than 15 years of experience, including employment with the Internal Revenue Service, and corporate accounting in the government contracting, manufacturing, and biotech industries. Mrs. Moran has been involved in all aspects of financial accounting, including financial reporting, budgeting, cost management, business projections and strategic planning.

Renata Hawthorne, PhD, Director, Brookwood Pharmaceuticals - Quality Control and Analytical Laboratory, has over 15 years of experience in Analytical Chemistry and instrumentation. She recently completed 1 1/2 years of teaching Chemistry at the University of Alabama in Birmingham. Dr. Hawthorne previously managed the Quality Control Analytical Laboratory at Southern BioSystems, Inc. (currently Durect Corporation.) She also managed the Analytical Development laboratory at BioCryst for 10 years, where she was involved with the set up of the laboratory, instrument purchasing, establishment of procedures for compliance with cGMPs, method development and validation. She began her analytical career working for the Alabama State Forensic Department conducting analyses in the toxicology laboratory. Dr. Hawthorne has contributed to more than 10 publications and presentations. She earned her doctorate in Physical Organic Chemistry from Auburn University in Alabama.

Robert J. Brady, Director, Brookwood Pharmaceuticals - Quality, is a quality professional with 34 years experience in the areas of Quality Assurance and cGMP, cGCP, and cGLP compliance. Prior to joining Brookwood he worked as an independent consultant to the pharmaceutical industry in the areas of compliance auditing, equipment and facility qualification, and clinical manufacturing. Mr. Brady gained his extensive quality management experience in positions of increasing responsibility with Boehringer Ingelheim Pharmaceuticals and Schering-Plough Corporation. He has presented at several professional meetings, most recently hosting a Webcast presentation on the current U.S. and E.U. cGMP requirements for the Regulatory Affairs Professionals Society (RAPS). Mr. Brady was a field Investigator for the U.S. Food and Drug Administration for thirteen years with experience in drug manufacturing primarily. In the FDA role, he worked in the Philadelphia, Boston and New Jersey District Offices on a variety of pharmaceutical facility inspections. He also has experience in inspections of biologics, medical devices and bioresearch monitoring activities. Bob is a graduate of Temple University in Philadelphia, PA with a B.A. degree in Anthropology.